investor cyclacel.com

Overview Cyclacel Pharmaceuticals, Inc.

The Investor Relations website contains information about Cyclacel Pharmaceuticals, Inc.s business for stockholders, potential investors, and financial analysts.

OVERVIEW

This domain investor.cyclacel.com presently has an average traffic classification of zero (the smaller the more users). We have scanned seventeen pages within the web site investor.cyclacel.com and found fifty-five websites interfacing with investor.cyclacel.com. There is two mass network sites linked to this website.
Pages Crawled
17
Links to this site
55
Social Links
2

INVESTOR.CYCLACEL.COM RANKINGS

This domain investor.cyclacel.com is seeing fluctuating amounts of traffic in the past the year.
Traffic for investor.cyclacel.com

Date Range

1 week
1 month
3 months
This Year
Last Year
All time
Traffic ranking (by month) for investor.cyclacel.com

Date Range

All time
This Year
Last Year
Traffic ranking by day of the week for investor.cyclacel.com

Date Range

All time
This Year
Last Year
Last Month

LINKS TO WEB SITE

Cyclacel Pharmaceuticals, Inc. Biopharmaceutical company developing cell cycle control cancer therapies

Drug Discovery and Development Approach. Cell cycle pioneers improving patients healthcare. With orally available innovative medicines.

WHAT DOES INVESTOR.CYCLACEL.COM LOOK LIKE?

Desktop Screenshot of investor.cyclacel.com Mobile Screenshot of investor.cyclacel.com Tablet Screenshot of investor.cyclacel.com

INVESTOR.CYCLACEL.COM HOST

I revealed that a lone root page on investor.cyclacel.com took three hundred and ten milliseconds to download. We could not find a SSL certificate, so we consider investor.cyclacel.com not secure.
Load time
0.31 secs
SSL
NOT SECURE
Internet Protocol
23.55.218.214

BROWSER ICON

SERVER OS

I observed that investor.cyclacel.com is employing the nginx os.

PAGE TITLE

Overview Cyclacel Pharmaceuticals, Inc.

DESCRIPTION

The Investor Relations website contains information about Cyclacel Pharmaceuticals, Inc.s business for stockholders, potential investors, and financial analysts.

CONTENT

This domain has the following in the homepage, "CYC116 Aurora Kinase and VEGFR2 Inhibitor." We analyzed that the web site also stated " Drug Discovery and Development Approach." It also stated " We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Cyclacel Pharmaceuticals, Inc. Fourth Quarter and Full Year 2017 Financial Results."

SEEK OTHER BUSINESSES

China Yuchai International Limited CYI - Investor Relations - Investors Home

Q2 2015 China Yuchai International Limited Earnings Conference Call. Q2 2015 China Yuchai International Limited Earnings Conference Call. Click here to add this event to your calendar. Currently, CYI holds 48.

Investor Relations Daktronics, Inc.

Daktronics designs, manufactures, sells and services dynamic visual communication systems for customers worldwide. Daktronics is a public corporation whose stock is traded on the Nasdaq national market under the symbol DAKT. Daktronics Unveils Major Innovation For Traffic Applications.

Darden Restaurants, Inc. - Investors - Investor Relations

The Darden family of restaurants features some of the most recognizable and successful brands in full-service dining. Through subsidiaries, we own and operate more than 1,600 restaurants, employ 165,000 people and serve 380 million guests a year. Be financially successful through great people consistently delivering outstanding food, drinks and service in an inviting atmosphere, making every guest loyal! March 22, 2018.

Delphi - Login

We can help you reset your password using your email address linked to your account. Your full suite of IR tools in one unique platform. This site is protected by Two-Factor Authentication. Please download Google Authenticator from the App Store for iOS or the Play Store for Android. For other devices, download an authenticator app from your device store. Enter the PIN to verify your identity. Need help? Remember this computer for 30.

Dendreon Corporation - News and Information

Dendreon Corporation is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients. Dendreon Announces Expiration of Bid Deadline In Connection With Agreement to Sell Substantially All Assets to Valeant. Stipulation of Settlement of Certain Shareholder Litigation.